overpayments

Risk Adjustment Basics and The Controversy Over Medicare RADV

A few readers have sent me messages and asked me to detail some basics of risk adjustment (RA) — how it works, its benefits, and its challenges — and the controversy surrounding risk adjustment data validation (RADV) in Medicare Advantage (MA) specifically. RA is a complex world, but here is my best effort to keep the overview simple and then move to the coming RADV conflagration. While not practiced in the employer world because of the penetration of self-insured funds under the Employee Retirement Income Security Act (ERISA, where the employer shoulders the entire burden of costs and insurers are not at risk), risk adjustment has become an important and common practice in MA, Medicaid managed care, and Exchange managed care. Quite simply, risk adjustment is critical to ensuring that health plans are compensated fairly to cover the costs of a given individual as well as the population as a

Read More »
Logo

January 3, 2024

Aggressive Agenda for Healthcare on Capitol Hill Good article on all the healthcare priorities for 2024.  This tracks very closely to my predictions for 2024 blog ( https://www.healthcarelabyrinth.com/channeling-nostradamus-the-healthcare-labyrinths-2024-predictions/ ). As I noted, a continuing resolution (CR) or other funding bill must pass soon to keep healthcare agencies open. As well, the article says that price transparency reporting, PBM reforms, and site-neutral payments are on the agenda. Note the reference to the long shot possibility of Medicare Advantage (MA) payment reductions. Troubled by prior authorization and overpayment headlines, Congress could take a bite out of rates for MA plans. This was also a possibility I raised in my predictions. There is also the issue of physician fee cuts in Medicare. (Article may require a subscription.) #transparency #pricetransparency #governmentshutdown # crs #siteneutral #pbms #medicareadvantage #medicare #overpayments #providers #rates Link to Article FDA Approvals Up FDA approvals of new novel drugs are up. 

Read More »

Channeling Nostradamus: The Healthcare Labyrinth’s 2024 Predictions

In my last blog, I gave you my healthcare year-in-review for 2023.  After that, as I always do each year, I play Nostradamus to prognosticate about what will happen in the next twelve months in the world of healthcare. Despite my Irish last name, I do have French blood (well, 50% French Canadien, so I count it). But I don’t claim to be an oracle or seer like our 16th century physician, apothecary, and astrologer friend. I do take a page from Nostradamus, though, in that my healthcare predictions for 2023 (not really prophecies) will be sometimes deliberately vague (they include a lot of mays, coulds, shoulds, and possibles) so as to amass a reasonable record for those tracking and putting together my forecasting report card for the history books. Here is hoping my crystal ball is clear and not cloudy, but don’t hold me to any of this; I am simply

Read More »

The Healthcare Labyrinth 2023 Year-In-Review

As I have done for many years, I write a healthcare year-in-review blog to tell you about all the major health stories and trends of the last twelve months. It is meant to be a general assessment and you can check this website’s Newsfeeds and Blogs as well as my LinkedIn posts ( https://www.linkedin.com/in/marc-s-ryan-%F0%9F%87%BA%F0%9F%87%A6-1a99529/ ) for more information.  I break the stories and trends into categories to help your understanding. It is clear that 2023 was a busy year for healthcare, so this blog will be a long one! Here we go! Healthcare, Insurers, and Providers In General In general, 2023 was a continuing year of recovery from the COVID pandemic (2020 to 2022). Healthcare utilization was up again and costs/inflation are returning to normal. We shall see this continue into 2024. We saw moderate inflation in the healthcare sector in 2023 with similar projections for next year (5% to

Read More »

Available Now

$30.00